Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -1677.17% is 718% below its 5-year average of -204.99%, near the low end of its 5-year range (-1677.17%–-33.42%).
331.03% below its 12-month average of -389.11%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q4 FY2026 (2026-03-31): -542.75%.
RETURN ON EQUITY (ROE)
-1677.17%
RETURN ON EQUITY (ROE) AVG TTM
-389.11%
RETURN ON EQUITY (ROE) AVG 3Y
-271.75%
RETURN ON EQUITY (ROE) AVG 5Y
-204.99%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-331.03%
CURRENT VS 3Y AVG
-517.18%
CURRENT VS 5Y AVG
-718.16%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 753 covered companies
CURRENT VS SECTOR MEDIAN
-3892.31%
vs the sector median at left
Beyond Air, Inc.
Market Cap
$1.84M
Return on Equity (ROE)
-1677.17%
TTM Avg
-389.11%
3Y Avg
-271.75%
5Y Avg
-204.99%
Market Cap
$1.84M
Return on Equity (ROE)
N/A
TTM Avg
-239.06%
3Y Avg
-695.85%
5Y Avg
-455.08%
Market Cap
$1.83M
Return on Equity (ROE)
N/A
TTM Avg
71.06%
3Y Avg
42.93%
5Y Avg
36.81%
Market Cap
$1.81M
Return on Equity (ROE)
-615.03%
TTM Avg
-210.38%
3Y Avg
-268.95%
5Y Avg
-212.66%
Market Cap
$1.88M
Return on Equity (ROE)
-30.92%
TTM Avg
247.31%
3Y Avg
-294.42%
5Y Avg
-190.41%
Market Cap
$1.88M
Return on Equity (ROE)
-509.36%
TTM Avg
-212.22%
3Y Avg
-233.92%
5Y Avg
-323.18%
Market Cap
$1.64M
Return on Equity (ROE)
-91.52%
TTM Avg
-77.16%
3Y Avg
-63.00%
5Y Avg
-74.35%
Market Cap
$2.13M
Return on Equity (ROE)
-1160.10%
TTM Avg
-528.10%
3Y Avg
-389.86%
5Y Avg
-336.02%
Market Cap
$2.14M
Return on Equity (ROE)
N/A
TTM Avg
642.41%
3Y Avg
-629.18%
5Y Avg
-444.57%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Beyond Air, Inc. (XAIR) | $1.84M | -1677.17% | -389.11% | -271.75% | -204.99% |
| Tenon Medical, Inc. (TNON)vs › | $1.84M | N/A | -239.06% | -695.85% | -455.08% |
| Profusa, Inc. Common Stock (PFSA)vs › | $1.83M | N/A | 71.06% | 42.93% | 36.81% |
| Alaunos Therapeutics, Inc. (TCRT)vs › | $1.81M | -615.03% | -210.38% | -268.95% | -212.66% |
| TransCode Therapeutics, Inc. (RNAZ)vs › | $1.88M | -30.92% | 247.31% | -294.42% | -190.41% |
| Autonomix Medical, Inc. (AMIX)vs › | $1.88M | -509.36% | -212.22% | -233.92% | -323.18% |
| Silo Pharma, Inc. (SILO)vs › | $1.64M | -91.52% | -77.16% | -63.00% | -74.35% |
| GeoVax Labs, Inc. (GOVX)vs › | $2.13M | -1160.10% | -528.10% | -389.86% | -336.02% |
| Vivos Therapeutics, Inc. (VVOS)vs › | $2.14M | N/A | 642.41% | -629.18% | -444.57% |
| Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs › | $1.52M | -169.64% | 97.92% | 65.28% | 65.28% |
ROE
-1677.2%
ROA
-101.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-03-31 | -542.75% |
| 2025-12-31 | -382.21% |
| 2025-09-30 | -288.20% |
| 2025-03-31 | -343.26% |
| 2024-12-31 | -296.42% |
| 2024-09-30 | -197.27% |
| 2024-06-30 | -361.74% |
| 2024-03-31 | -240.51% |
| 2023-12-31 | -320.45% |
| 2023-09-30 | -245.59% |
| 2023-06-30 | -166.34% |
| 2023-03-31 | -147.21% |
| 2022-12-31 | -109.24% |
| 2022-09-30 | -86.12% |
| 2022-06-30 | -71.64% |
| 2022-03-31 | -59.39% |
| 2021-12-31 | -33.42% |
| 2021-09-30 | -64.60% |
| 2021-06-30 | -68.39% |
| 2021-03-31 | -75.09% |
| 2020-12-31 | -133.13% |
| 2020-09-30 | -133.52% |
| 2020-06-30 | -112.40% |
| 2020-03-31 | -110.23% |
| 2019-12-31 | -122.60% |
| 2019-09-30 | -169.92% |
| 2019-06-30 | -123.97% |
| 2019-03-31 | -163.09% |
| 2018-12-31 | -222.26% |
| 2018-03-31 | -693.76% |
| 2017-03-31 | -840.61% |
